๐ Statistics
- Analyst 1 Year Price Target:
-
- Upside/Downside from Analyst Target:
-
- Broker Call:
-
- Dividend Minimum 3 Year Yield:
-
- EPS Growth Range (1Y):
-
- Net Income Growth Range (1Y):
-
- Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
๐ฐ Dividend History
Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
2019 |
- |
$0.000000 |
- |
2019-12-13 |
- |
Ratio: 4:1
|
Total Amount for 2019: $0.000000 |
๐
SGX Earnings Announcements for 505
AsiaMedic Limited (505)
Market: SGX |
Currency: SGD
Address: No. 08-00 Shaw House
AsiaMedic Limited, an investment holding company, provides healthcare services in Singapore. The company offers diagnostic imaging, radiology, health screening, and medical wellness services. It also provides medical aesthetic products and related services. In addition, the company provides medical imaging services, such as computerized and positron emission tomography; bone mineral densitometry, and magnetic resonance imaging, as well as ultrasound scanning and X-ray. Further, it operates aesthetic clinics. Additionally, the company sells pharmaceutical and aesthetic related products. The company was incorporated in 1974 and is based in Singapore.
๐ AsiaMedic Limited Historical Chart
๐งพ Recent Financial Statement Analysis
August 12, 2025
AsiaMedic Limited 1H2025 Financial Analysis: Ramp-Up Expansion and Profitability Headwinds AsiaMedic Limited, a Catalist-listed healthcare provider in Singapore, released its unaudited consolidated financial statements for the six months ended 30 June 2025. The report reveals a period of strong revenue…
๐ View more in SGX corporate News ๐ View more in SGX Financial statements
๐ฐ Related News & Research
Showing results matched by any of: 505.SI, AsiaMedic Limited, AsiaMedic, AMAT SP, ASIAMEDIC LTD, ASIAMEDIC
August 12, 2025
AsiaMedic Limited 1H2025 Financial Analysis: Ramp-Up Expansion and Profitability Headwinds AsiaMedic Limited, a Catalist-listed healthcare provider in Singapore, released its unaudited consolidated financial statements for the six months ended 30 June 2025. The report reveals a period of strong revenue…